Scientists Find 26 Genetic Clues Behind Fibromyalgia

For decades, fibromyalgia patients have faced a frustrating problem: the pain was real, but medicine had no blood test or scan that could clearly show why. Now, the largest genetic study of the condition ever conducted has uncovered 26 regions of the genome linked to fibromyalgia risk.

The findings point strongly toward the nervous system and could change how researchers investigate chronic pain. For people who have spent years being told that their symptoms were difficult to explain, the study offers something medicine has long struggled to provide: clear biological leads.

Fibromyalgia Was Once Diagnosed With Pressure Points

Fibromyalgia affects roughly 2% of people globally, although estimates vary depending on how cases are counted. It is diagnosed about three times more often in women than in men.

For years, doctors relied heavily on symptoms such as widespread pain, exhaustion, sleep problems, and cognitive difficulties often called “fibro fog.” Under a 1990 classification standard, doctors also applied four kilograms of pressure to 18 specific spots on the body.

If at least 11 of those points were painful, a patient could meet the classification criteria. The tender-point examination was eventually replaced by symptom-based assessments, but there was still no biological marker that could settle the question.

Researchers knew the condition appeared to run in families, yet strong genetic risk factors had remained difficult to find. “We were struck by the fact that, despite being known to run in families, no one had found any robust genetic risk factors for fibromyalgia,” said Michael Wainberg of the Lunenfeld-Tanenbaum Research Institute and the University of Toronto.

More Than 2.5 Million People Were Studied

The study, published in Nature Medicine on July 28, 2026, brought together genetic data on a scale previous fibromyalgia research had not reached. Researchers combined 11 cohorts from six countries and analyzed 2,563,755 people.

The dataset included 54,629 people carrying a fibromyalgia diagnosis and more than 2.5 million controls. From that enormous pool, researchers identified 26 regions of the genome associated with fibromyalgia risk.

Hanna Ollila, a genetic epidemiologist at the University of Helsinki, said the combined findings were striking. “I was very positively surprised how coherent all of the associations at the end were when we combined all of the data across the 11 cohorts,” she said.

The sheer size of the study gave researchers a better chance of detecting genetic signals with small individual effects. That matters because common genetic variants can influence risk without determining whether someone will develop a condition.

The Study’s Key Numbers

The project became the largest genetic investigation of fibromyalgia to date. Its scale can be broken down into a few major figures:

• 11 cohorts: Multiple biobanks and research groups contributed data.
• Six countries: The research included several national datasets.
• 2,563,755 participants: The huge sample increased the study’s statistical power.
• 54,629 fibromyalgia cases: These participants helped researchers identify shared patterns.
• 26 genomic regions: The study linked these regions with fibromyalgia risk.

The discovery does not create a genetic test for fibromyalgia. Instead, it gives scientists a detailed map of biological pathways that now deserve closer investigation.

The Strongest Signal Came From the Huntington’s Gene

The study’s strongest genetic signal appeared in HTT, the gene best known for its role in Huntington’s disease. That connection was one of the biggest surprises in the research.

The variant involves a single amino acid missing from the huntingtin protein and raises the odds of a fibromyalgia diagnosis by about 9%. It is not the Huntington’s disease mutation and does not carry Huntington’s risk.

“Finding any link at all to the ‘Huntington’s gene’ was completely unexpected and gives us a concrete lead into the biology at play in fibromyalgia,” Wainberg told reporters. The finding gives researchers a specific pathway they can now investigate further.

The increased risk should also be kept in perspective. According to neurologist Jose-Alberto Palma’s analysis of the data, roughly 97 out of every 100 carriers of the variant will never develop fibromyalgia.

Nearly Every Major Signal Pointed to the Brain

Researchers also examined where the genes associated with fibromyalgia appeared to do their work. The result was striking: the strongest signals were concentrated in brain tissue and neural cell types.

Of the 13 cell types showing significant enrichment, 12 were neurons. The strongest association involved neurons in the dentate gyrus, a part of the hippocampus.

Researchers did not find the same signal in muscle or connective tissue. “Many of the risk factors we found point towards the nervous system rather than the immune system,” Wainberg said.

That finding does not mean fibromyalgia is “all in the mind,” a dismissive phrase many patients have encountered when conventional tests failed to provide answers. Instead, the study suggests that biological processes involved in the condition may be connected to how the nervous system processes and regulates pain.

“This work changes how we think about fibromyalgia at a fundamental level,” Wainberg said. “For decades, patients have been dismissed or told their pain is simply psychological. Our findings confirm the condition has a clear biological basis.”

Fibromyalgia Also Shared Genetic Links With Other Conditions

The genetic patterns did not exist in isolation. Researchers found strong overlap between fibromyalgia and conditions including low back pain, post-traumatic stress disorder, and irritable bowel syndrome.

Some of those genetic correlations climbed above 0.7 on a scale where 1.0 would represent identical genetic architecture. Overlap with autoimmune conditions was present but more modest.

Frances Williams of King’s College London said the findings could encourage researchers to look at chronic pain conditions as part of a connected biological picture. “We know that chronic pain syndromes cluster together in individuals and families and are genetically similar,” she said.

Williams added that targeting shared mechanisms could potentially benefit a wider group of disorders. The study also found that genetic architecture appeared almost identical between men and women, despite nearly 88% of cases in the dataset being women.

The Study Does Have Important Limitations

The enormous size of the research does not make it a final answer. Participants were counted as fibromyalgia cases if their medical records contained the billing code M79.7 at least once.

Researchers did not independently confirm every diagnosis, and the percentage of participants carrying the code varied widely between cohorts. It ranged from 1.2% in the Estonian Biobank to 7.5% in the Michigan cohort.

The genetic effects were also relatively small, with common variants explaining about 10.4% of the variation in risk. The study population was overwhelmingly of European ancestry, meaning future research will need to examine more diverse groups.

These findings cannot diagnose fibromyalgia or predict with certainty who will develop it. The research is better viewed as a map showing scientists where they should look next.

One Genetic Lead Could Eventually Influence Drug Research

One of the study’s most interesting targets is GPR52, a receptor involved in regulating HTT levels. It was flagged by the researchers’ gene prioritization analysis and is already being investigated in Huntington’s disease research.

That does not mean a new fibromyalgia medication is ready for patients. Still, treatments developed for one condition can sometimes be investigated for another when researchers identify overlapping biological pathways.

Other prioritized genes, including CELF4 and DCC, also sit within neural pathways that could offer further clues. Nasa Sinnott-Armstrong, a geneticist at the University of Washington, said broader chronic pain research could eventually lead to better therapies and diagnoses.

Nothing about the study changes what patients should do today. Current approaches described in the source include graded exercise, better sleep, pacing, cognitive behavioral approaches, and a small number of approved medications with modest benefits.

The major change is happening inside the research world. For decades, fibromyalgia had symptoms that patients could describe but few biological clues for scientists to follow, and now researchers have 26 genetic regions pointing them toward new questions about pain.